Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Customer Officer | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,172 |
Reported balance
After 2023-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-06 · Sale · Disposed 1,014 · Balance 39,172 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2: Includes an aggregate of 416 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022 and December 2022. |
| Common StockSEC Table I · non-derivative | Direct | 38,115 |
Reported balance
After 2023-06-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-06-07 · Sale · Disposed 1,057 · Balance 38,115 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2: Includes an aggregate of 416 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022 and December 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 8, 2023 01:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,057 | $37.87 | $40,023.31 |
DisclosureSEC source: 0001209191-23-035258 · doc4.xml · nonDerivative · entry 2 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,115 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,014 | $38.99 | $39,536.87 |
DisclosureSEC source: 0001209191-23-035258 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,172 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes an aggregate of 416 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022 and December 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 19,900 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035225 · doc4.xml · derivative · entry 3 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Underlying: Common Stock · 19,900 shares Expires 2032-06-08 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035225 · doc4.xml · nonDerivative · entry 2 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,770 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,140 | $61.37 | $131,340.36 |
DisclosureSEC source: 0001209191-22-035225 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,820 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 258 and 161 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021 and December 2021, respectively. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040098 · doc4.xml · derivative · entry 2 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040098 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,541 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,895 | $61.04 | $115,665.12 |
DisclosureSEC source: 0001209191-21-038884 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Customer Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,541 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 355 and 183 shares of common stock acquired under the issuer's employee stock purchase plan in June 2020 and December 2020, respectively. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036047 · doc4.xml · derivative · entry 2 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036047 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,898 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,447 | $46.33 | $67,040.96 |
DisclosureSEC source: 0001209191-20-035172 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,898 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 229 shares of common stock acquired under the issuer's employee stock purchase plan in December 2019. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 23:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,671 | $45.79 | $168,107.94 |
DisclosureSEC source: 0001209191-19-061186 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,116 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.73 to $45.81, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 365 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:50 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 33,800 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035115 · doc4.xml · derivative · entry 3 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,800 Underlying: Common Stock · 33,800 shares Expires 2029-06-05 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:50 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035115 · doc4.xml · nonDerivative · entry 2 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,422 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:50 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,099 | $42.91 | $47,158.09 |
DisclosureSEC source: 0001209191-19-035115 · doc4.xml · nonDerivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,822 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 88 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $46.55 | $0.00 |
DisclosureSEC source: 0001209191-18-050102 · doc4.xml · derivative · entry 1 McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on August 29, 2019, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.